Ticker Details
Spero Therapeutics, Inc. Spero Therapeutics Inc is a multi asset clinical stage biopharmaceutical company. It is focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
IPO Date:	November 2, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$129.58M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.23 | 3.03%
Avg Daily Range (30 D):	$0.04 | 1.83%
Avg Daily Range (90 D):	$0.05 | 2.11%

Institutional Daily Volume
Avg Daily Volume:	.57M
Avg Daily Volume (30 D):	.28M
Avg Daily Volume (90 D):	.46M

Trade Size
Avg Trade Size (Sh.):	246
Avg Trade Size (Sh.) (30 D):	184
Avg Trade Size (Sh.) (90 D):	181

Institutional Trades
Total Institutional Trades:	98
Avg Institutional Trade:	$1.68M
Avg Institutional Trade (30 D):	$.61M
Avg Institutional Trade (90 D):	$.61M
Avg Institutional Trade Volume:	.19M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.03M
Avg Closing Trade (30 D):	$1.11M
Avg Closing Trade (90 D):	$1.11M
Avg Closing Volume:	300.61K

News

Nov 28, 2025 @ 1:00 PM Spero Therapeutics Announces Inducement Grant Unde... Source: Spero Therapeutics

Jan 10, 2025 @ 12:00 PM Spero Therapeutics Provides Business Update and An... Source: Spero Therapeutics

Jul 3, 2024 @ 5:07 PM Spero Therapeutics Announces Inducement Grant Unde... Source: N/A

Jun 24, 2024 @ 1:07 PM Denali Therapeutics (DNLI) Moves 5.8% Higher: Will... Source: Zacks Equity Research

Jun 3, 2024 @ 8:05 PM Spero Therapeutics Announces Inducement Grant Unde... Source: Spero Therapeutics, Inc.

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.79	$-.13	$-.03
Diluted EPS	$-.79	$-.13	$-.03
Revenue	$40.55M	$5.44M	$14.19M
Gross Profit
Net Income / Loss	$-43.84M	$-7.38M	$-1.7M
Operating Income / Loss	$-46.82M	$-7.92M	$-2.44M
Cost of Revenue
Net Cash Flow	$-27.67M	$17.42M	$-17.69M
PE Ratio